Study reveals AI can predict patients’ survival in glioblastoma
The aggressive brain cancer is responsible for over 3,000 cases in the UK every year
Read More
Tag: Glioblastoma
Debiopharm commences pivotal glioblastoma therapy study
The therapy is a brain-penetrant used in various combinations in patients with progressive glioblastoma
Read More
Early promise for new immunotherapy combo in brain cancer
Experimental drug plus immunotherapy demonstrated early potential in aggressive brain cancer
Read More
AbbVie ends Phase III brain tumour study due to failed primary goal
Enrolment in all ongoing Depatux-M studies has been halted.
Read More
NICE backs use of dye for brain tumour removal
NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours.
Read More
Avastin wins full green light for glioblastoma
Roche group Genentech has announced full US approval for Avastin for the treatment of adults with glioblastoma that progressed following prior therapy.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
